Literature DB >> 18352782

Hospital care for children with hydrocephalus in the United States: utilization, charges, comorbidities, and deaths.

Tamara D Simon1, Jay Riva-Cambrin, Raj Srivastava, Susan L Bratton, J Michael Dean, John R W Kestle.   

Abstract

OBJECT: The aims of this study were to measure inpatient health care for pediatric hydrocephalus in the US; describe patient, hospital, and hospitalization characteristics for pediatric hydrocephalus inpatient care; and determine characteristics associated with death.
METHODS: A cross-sectional study was performed using the 1997, 2000, and 2003 Healthcare Cost and Utilization Project Kids' Inpatient Databases (KID), nationally representative weighted data sets of hospital discharges for pediatric patients. A hydrocephalus-related hospitalization was classified as either cerebrospinal fluid (CSF) shunt-related (including initial placements, infections, malfunctions, or other) or non-CSF shunt-related. Patients>18 years of age were excluded. The KID provided weighted estimates of 6.657, 6.597, and 6.732 million total discharges in the 3 study years.
RESULTS: Each year there were 38,200-39,900 admissions, 391,000-433,000 hospital days, and total hospital charges of $1.4-2.0 billion for pediatric hydrocephalus. Hydrocephalus accounted for 0.6% of all pediatric hospital admissions in the US in 2003, but for 1.8% of all pediatric hospital days and 3.1% of all pediatric hospital charges. Over the study years, children admitted with hydrocephalus were older, had an increase in comorbidities, and were admitted more frequently to teaching hospitals. Compared with children who survived, those who died were more likely to be <3 months of age and have a birth-related admission, have no insurance, have comorbidities, be transferred, and have a non-CSF shunt-related admission.
CONCLUSIONS: Children with hydrocephalus have a chronic illness and use a disproportionate share of hospital days and healthcare dollars in the US. Since 1997 they have increased in age and in number of comorbid conditions. For important changes in morbidity and mortality rates to be made, focused research efforts and funding are necessary.

Entities:  

Mesh:

Year:  2008        PMID: 18352782     DOI: 10.3171/PED/2008/1/2/131

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  77 in total

1.  Shortfalls in pediatric hydrocephalus clinical outcome analysis.

Authors:  Mohammad Sami Walid; Joe Sam Robinson
Journal:  Childs Nerv Syst       Date:  2012-01-25       Impact factor: 1.475

Review 2.  Ventricular shunt infections: immunopathogenesis and clinical management.

Authors:  Yenis Gutierrez-Murgas; Jessica N Snowden
Journal:  J Neuroimmunol       Date:  2014-08-13       Impact factor: 3.478

3.  Hydrocephalus decreases arterial spin-labeled cerebral perfusion.

Authors:  K W Yeom; R M Lober; A Alexander; S H Cheshier; M S B Edwards
Journal:  AJNR Am J Neuroradiol       Date:  2014-03-20       Impact factor: 3.825

Review 4.  Who will care for me next? Transitioning to adulthood with hydrocephalus.

Authors:  Tamara D Simon; Sara Lamb; Nancy A Murphy; Bonnie Hom; Marion L Walker; Edward B Clark
Journal:  Pediatrics       Date:  2009-10-19       Impact factor: 7.124

5.  Few Patient, Treatment, and Diagnostic or Microbiological Factors, Except Complications and Intermittent Negative Cerebrospinal Fluid (CSF) Cultures During First CSF Shunt Infection, Are Associated With Reinfection.

Authors:  Tamara D Simon; Nicole Mayer-Hamblett; Kathryn B Whitlock; Marcie Langley; John R W Kestle; Jay Riva-Cambrin; Margaret Rosenfeld; Emily A Thorell
Journal:  J Pediatric Infect Dis Soc       Date:  2013-08-26       Impact factor: 3.164

6.  Transverse sinus stenting for pseudotumor cerebri: a cost comparison with CSF shunting.

Authors:  R M Ahmed; F Zmudzki; G D Parker; B K Owler; G M Halmagyi
Journal:  AJNR Am J Neuroradiol       Date:  2013-11-28       Impact factor: 3.825

7.  Management of exposed ventriculoperitoneal shunt on the scalp in pediatric patients.

Authors:  Osman Akdag
Journal:  Childs Nerv Syst       Date:  2018-02-02       Impact factor: 1.475

8.  Reinfection after treatment of first cerebrospinal fluid shunt infection: a prospective observational cohort study.

Authors:  Tamara D Simon; Matthew P Kronman; Kathryn B Whitlock; Nancy E Gove; Nicole Mayer-Hamblett; Samuel R Browd; D Douglas Cochrane; Richard Holubkov; Abhaya V Kulkarni; Marcie Langley; David D Limbrick; Thomas G Luerssen; W Jerry Oakes; Jay Riva-Cambrin; Curtis Rozzelle; Chevis Shannon; Mandeep Tamber; John C Wellons; William E Whitehead; John R W Kestle
Journal:  J Neurosurg Pediatr       Date:  2018-02-02       Impact factor: 2.375

9.  Variability in Management of First Cerebrospinal Fluid Shunt Infection: A Prospective Multi-Institutional Observational Cohort Study.

Authors:  Tamara D Simon; Matthew P Kronman; Kathryn B Whitlock; Nancy Gove; Samuel R Browd; Richard Holubkov; John R W Kestle; Abhaya V Kulkarni; Marcie Langley; David D Limbrick; Thomas G Luerssen; Jerry Oakes; Jay Riva-Cambrin; Curtis Rozzelle; Chevis Shannon; Mandeep Tamber; John C Wellons; William E Whitehead; Nicole Mayer-Hamblett
Journal:  J Pediatr       Date:  2016-09-28       Impact factor: 4.406

10.  Soluble membrane attack complex is diagnostic for intraventricular shunt infection in children.

Authors:  Theresa N Ramos; Anastasia A Arynchyna; Tessa E Blackburn; Scott R Barnum; James M Johnston
Journal:  JCI Insight       Date:  2016-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.